Study of TPX-0022 in Patients With Advanced NSCLC, Gastric Cancer or Solid Tumors Harboring Genetic Alterations in MET

Clinical trial NCT03993873 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03993873
Sponsor: Turning Point Therapeutics, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Advanced Solid Tumor Metastatic Solid Tumors MET Gene Alterations

Start date: 2019-09-05
Primary completion: 2024-01-08
Enrollment: 95

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.